ArticleFrontiers in pediatrics2026
Breaking the sound barrier: global monoclonal antibody pharmacoequity.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies represent one of biomedicine's greatest successes, yet global access remains profoundly inequitable, with low- and middle-income countries bearing the brunt of limited access. This perspective proposes that long-acting infectious disease mAbs, starting with WHO-recommended nirsevimab for RSV prevention, could catalyze transformation by connecting with existing WHO Essential Medicines List mAbs. Picture two static half-circles: WHO Essential Medicines List mAbs with proven value but limited access, and infectious disease prevention mAbs with transformative potential. Connected, they form a complete wheel capable of rolling toward the aspirations of global pharmacoequity. HIV antiretroviral therapy demonstrates precedent-costs declined 100-fold through political mobilization, not technological breakthroughs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.